Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.3582
−$0.0261 · -6.79%
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
Latest quote
$0.3582
−$0.0261 · -6.79%
After-hours
$0.36
+$0.0018 · +0.50%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
Day range
Current $0.3582
52-week range
Current $0.3582
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
65
Undervalued
Sentiment
49
Mixed
Risk
74
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
Day range
Current $0.3582
52-week range
Current $0.3582
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 154.9M USD | 144.29M USD | 127.04M USD | 107.67M USD | 86.35M USD |
| Cost of goods sold | 41.35M USD | 38.65M USD | 65.11M USD | 54.87M USD | 46.02M USD |
| Gross profit | 113.56M USD | 105.64M USD | 61.94M USD | 52.8M USD | 40.33M USD |
| Research and development | 12.43M USD | 16.68M USD | 39.13M USD | 82.7M USD | 130.82M USD |
| Selling, general, and administrative | 103.67M USD | 100.48M USD | 119.82M USD | 144.75M USD | 127.33M USD |
| Operating expenses | 116.1M USD | 117.17M USD | 172.55M USD | 227.46M USD | 258.15M USD |
| Interest income | — | 3.55M USD | 3.36M USD | 1.64M USD | 433K USD |
| Interest expense | — | 6.03M USD | 3.87M USD | 2.47M USD | 2.41M USD |
| Depreciation and amortization | 2.31M USD | 2.49M USD | 2.9M USD | 2.89M USD | 3.02M USD |
| Operating income | −2.54M USD | −11.53M USD | −110.62M USD | −174.66M USD | −217.83M USD |
| Net income | −20.2M USD | −13.58M USD | −110.56M USD | −182.02M USD | −220.68M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$6.67
1762.09% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 13, 2014 | 1:20 | — | — |
Stock split | May 25, 2007 | 1:4 | — | — |
Effective Jan 13, 2014
1:20
Effective May 25, 2007
1:4
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.74M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM1.44M0.00%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF668.05K0.00%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO356K0.00%14.04B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO291.04K0.00%18B USD0.06%$112.1-0.10%
iShares Micro-Cap ETFIWC179.33K0.01%1.33B USD0.60%$182.79-0.31%
Invesco NASDAQ Future Gen 200 ETFQQQS144.85K0.64%22.96M USD0.20%$41.5683-1.09%
Vanguard Health Care ETFVHT104.08K0.00%22B USD0.09%$313.85-0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCInvesco NASDAQ Future Gen 200 ETFQQQSVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
